Radical resection and reconstruction in patients with adenoid cystic carcinoma in the minor salivary glands of the palate

腭部小唾液腺腺样囊性癌患者的根治性切除和重建

阅读:1

Abstract

BACKGROUND: This study evaluated the clinical outcomes of the patients with adenoid cystic carcinoma (ACC) of the minor salivary glands of the palate. METHODS: Forty-four patients with stage I-II disease and 14 patients with stage III-IV disease underwent radical excision and reconstruction with a facial-submental artery island flap (FSAIF) and titanium mesh plus a free anterolateral thigh flap (ALTF) and radiotherapy respectively. Patients with stage III-IV disease subsequently received cobalt Co 60 adjuvant radiotherapy. Ki-67 expression was determined semiquantitatively in 52 patients with ACC by based on the cytoplasm staining intensity and percentage of positively stained tumor cells. RESULTS: The median (range) follow-up was 32.9 (14-58) months. Forty-one (71.7%) patients survived without disease recurrence. Nine patients (15.5%) survived with recurrent tumors (four with local recurrence, three with regional recurrence requiring salvage surgery, and two with distant metastasis); among these patients, five had overlapping recurrence. Eight patients (13.8%) died of regional, distant, or multiorgan metastasis (range: 22-42 months). The overall median (95% CI) survival time was 32.5 (25.0-39.5) months, and the median (95% CI) progression-free survival time was 32.9 (28.5-36.9) months. Rates of survival and recurrence differed significantly between patients with low- and high-grade tumors, patients with clinical stage I-II disease and those with stage III-IV disease, patients with and without lymph node metastasis, patients who underwent radical excision with versus without radiotherapy, and patients with low and high Ki-67 expression. CONCLUSION: Radical resection and reconstruction with FSAIF is suitable methods for the the treatment of stage I-II ACC of the minor salivary glands of the palate. Stage III-IV tumors require radical resection, reconstruction with titanium mesh and free ALTF, and radiotherapy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。